Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples